Introducing the Sefia™ platform
Have you seen it? View the virtual launch event on demand.
Sefia™ cell therapy manufacturing platform: an end-to-end CAR T manufacturing solution.
Deliver what’s next in CAR T manufacturing
When it comes to cell therapy manufacturing, you’re not just in production. You’re crafting hope for millions awaiting these breakthrough treatments. And excelling on this path to commercial realization craves the support of a platform made specifically for cell therapy manufacturing. A platform that not only provides flexibility and easy integration, but also boosts productivity and automates key steps of your workflow.
Breakaway from asking “what if”… it’s time to get after "what’s next."
eBook: Navigating cell therapy process development
What are the four main challenges and, more importantly, how can you overcome them?
One of the main challenges of manufacturing autologous CAR T cell therapy is the cost. Open, manual operations are error- and contamination-prone. And if you’re thinking of scaling, the probability of these errors might just scale with you. But you can reduce the risk—while keeping flexibility—with closed and automated systems. Automation brings formerly discrete steps together, saving you time and money. Plus, by standardizing your process, you’re one step closer to meeting regulatory requirements—and to safely delivering your therapies to patients.